Liability Issues in Pharmacogenomics
Year: 2005
Type: preprint
Abstract: Liability concers involving toxicogenomics inevitably raise broad issues of ethics and policy. The first of these issues, often called exceptionalism deals with wether genetic is so unique that is should be considered seperately from other medical information. In other words, is there something different about pharmacogenomics as opposed to any other pharmaceutical research discipline? Is there something unique about drug development strategies and drug regulation involving pharmacogenomics compared with traditional drug development strategies and regulation? Is there something different about liabilty issues for manufacturers and health care providers involved with this technology? These question will inform our analysis of pharmacogenomics.
Source: SSRN Electronic Journal
Author: Mark A. Rothstein
Institutions: Louisiana State University, University of Louisville
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1523102492